ArticleDiscover oncology2026
AKAP7 is a prognostic biomarker involved in immune infiltration of bladder urothelial carcinoma and correlated with ferroptosis.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundBladder urothelial carcinoma (BLCA) is a common urinary malignancy, and the identification of appropriate biomarkers remains a significant challenge. AKAP7 is a molecular scaffolding protein that plays a crucial role in spatially regulating cyclic adenosine monophosphate (cAMP) signaling through its ability to anchor protein kinase A (PKA) to the cytoskeleton. This study aims to explore the expression level, prognostic implications and immune characteristics of AKAP7 in BLCA.
methodsBased on numerous databases, including CCLE, HPA, Harmonizome, TCGA, GEO, GEPIA2, Kaplan-Meier plotters, GENT2, cBioPortal and the COSMIC databases, we explored the expression pattern, prognostic value and gene alteration and mutation of AKAP7. The potential molecular mechanisms of AKAP7 were analyzed via the Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis. Furthermore, using single-cell RNA-seq datasets, we investigated the distribution of AKAP7 in tumor microenvironments (TME). We utilized the TISIDB database to analyze the association between AKAP7 and immune characteristics. Additionally, we explored the correlation between AKAP7 expression and ferroptosis using TCGA and GEO data sets. Finally, we verified the expression level of AKAP7 in clinical samples of BLCA as well as BLCA cell lines.
resultsCompared with normal tissues, we observed a decreased expression level of AKAP7 in BLCA tissues. BLCA patients with low AKAP7 expression showed poor prognosis. The expression of AKAP7 had a significant positive correlation with the infiltration of T helper cells, Tcm, Eosinopoils, TFH, Th17 and CD8 T cells. The TCGA and GEO datasets suggested that the expression of AKAP7 was closely associated with a ferroptosis-related gene Acyl-CoA synthetase long-chain family member 4 (ACSL4).
conclusionAKAP7 may play a critical role in the prognosis and immune regulation of BLCA prognosis. Besides, it is related to ferroptosis. AKAP7 is an effective biomarker in BLCA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.